ras	B-protein
protein	I-protein
activity	O
is	O
essential	O
for	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
signal	O
transduction	O
.	O

In	O
a	O
Jurkat	B-cell_line
cell	I-cell_line
model	I-cell_line
of	O
T-cell	O
activation	O
an	O
interleukin-2	B-DNA
promoter/reporter	I-DNA
gene	I-DNA
construct	I-DNA
was	O
activated	O
by	O
antigen	B-protein
receptor	I-protein
agonism	O
in	O
combination	O
with	O
the	O
lymphokine	B-protein
interleukin-1	B-protein
.	O

Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O

In	O
cotransfection	O
experiments	O
,	O
oncogenic	O
rats	O
obviated	O
the	O
need	O
for	O
PKC	B-protein
stimulation	O
but	O
did	O
not	O
replace	O
either	O
the	O
calcium	O
signal	O
or	O
interleukin-1	B-protein
.	O

Activated	O
ras	B-protein
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	B-protein
stimulation	O
in	O
activation	O
of	O
the	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
NF-AT	B-protein
.	O

A	O
dominant	B-protein
inhibitory	I-protein
ras	I-protein
mutant	I-protein
specifically	O
blocked	O
antigen	O
receptor	O
agonism	O
,	O
indicating	O
that	O
ras	B-protein
activity	O
is	O
required	O
for	O
antigen	B-protein
receptor	I-protein
signaling	O
.	O

In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	B-protein
blocked	O
both	O
activated	O
ras	B-protein
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	B-protein
upstream	O
of	O
PKC	B-protein
.	O

THE	NULL
Journar	NULL
or	NULL
Biorocicat	NULL
CHEMISTRY	NULL
.	NULL

©1993	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

268	NULL
,	NULL
No	NULL
.	NULL

4	NULL
,	NULL
Issue	NULL
of	NULL
February	NULL
5	NULL
,	NULL
pp	NULL
.	NULL

2693-2698	NULL
,	NULL
1993	NULL
Printed	NULL
in	NULL
U.8.A	NULL
.	NULL

ras	NULL
Protein	NULL
Activity	NULL
Is	NULL
Essential	NULL
for	NULL
T-cell	NULL
Antigen	NULL
Receptor	NULL
Signal	NULL
Transduction*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
June	NULL
8	NULL
,	NULL
1992	NULL
)	NULL
Cosima	NULL
T.	NULL
Baldari	NULL
#	NULL
,	NULL
Adriana	NULL
Heguy§	NULL
,	NULL
and	NULL
John	NULL
L.	NULL
Telford	NULL
{	NULL
§	NULL
{	NULL
From	NULL
the	NULL
$	NULL
Department	NULL
of	NULL
Evolutionary	NULL
Biology	NULL
,	NULL
University	NULL
of	NULL
Siena	NULL
,	NULL
Via	NULL
Mattioli	NULL
4	NULL
,	NULL
53100	NULL
Siena	NULL
,	NULL
Italy	NULL
and	NULL
the	NULL
§Immunobiological	NULL
Research	NULL
Institute	NULL
,	NULL
Siena	NULL
,	NULL
Via	NULL
Fiorentina	NULL
1	NULL
,	NULL
53100	NULL
Siena	NULL
,	NULL
Italy	NULL
In	NULL
a	NULL
Jurkat	NULL
cell	NULL
model	NULL
of	NULL
T-cell	NULL
activation	NULL
an	NULL
interleukin-2	NULL
promoter/reporter	NULL
gene	NULL
construct	NULL
was	NULL
activated	NULL
by	NULL
antigen	NULL
receptor	NULL
agonism	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
lymphokine	NULL
interleukin-1	NULL
.	NULL

Antigen	NULL
receptor	NULL
signals	NULL
could	NULL
be	NULL
mimicked	NULL
by	NULL
suboptimal	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
with	NULL
phorbol	NULL
esters	NULL
in	NULL
combination	NULL
with	NULL
calcium	NULL
mobilization	NULL
by	NULL
an	NULL
ionophore	NULL
.	NULL

In	NULL
cotransfection	NULL
experiments	NULL
,	NULL
oncogenic	NULL
ras	NULL
obviated	NULL
the	NULL
need	NULL
for	NULL
PKC	NULL
stimulation	NULL
but	NULL
did	NULL
not	NULL
replace	NULL
either	NULL
the	NULL
calcium	NULL
signal	NULL
or	NULL
interleukin-1	NULL
.	NULL

Activated	NULL
ras	NULL
expression	NULL
also	NULL
replaced	NULL
the	NULL
requirement	NULL
for	NULL
PKC	NULL
stimulation	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
T-cell	NULL
transcription	NULL
factor	NULL
NF-AT	NULL
.	NULL

A	NULL
dominant	NULL
inhibitory	NULL
ras	NULL
mutant	NULL
specifically	NULL
blocked	NULL
antigen	NULL
receptor	NULL
agonism	NULL
,	NULL
indicating	NULL
that	NULL
ras	NULL
activity	NULL
is	NULL
required	NULL
for	NULL
antigen	NULL
receptor	NULL
signaling	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
PKC	NULL
blocked	NULL
both	NULL
activated	NULL
ras	NULL
and	NULL
phorbol	NULL
ester	NULL
stimulation	NULL
,	NULL
suggesting	NULL
a	NULL
role	NULL
for	NULL
ras	NULL
upstream	NULL
of	NULL
PKC	NULL
.	NULL

Activation	NULL
of	NULL
resting	NULL
T-cells	NULL
is	NULL
triggered	NULL
by	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
recognition	NULL
of	NULL
a	NULL
specific	NULL
antigen	NULL
complexed	NULL
to	NULL
major	NULL
histocompatibility	NULL
proteins	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
antigen-presenting	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
TCR	NULL
engagement	NULL
,	NULL
induction	NULL
of	NULL
T-cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
requires	NULL
accessory	NULL
signals	NULL
which	NULL
can	NULL
be	NULL
supplied	NULL
in	NULL
the	NULL
form	NULL
of	NULL
lymphokines	NULL
by	NULL
the	NULL
antigen-presenting	NULL
cell	NULL
.	NULL

TCR	NULL
engagement	NULL
results	NULL
in	NULL
transient	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
and	NULL
a	NULL
sustained	NULL
increase	NULL
in	NULL
intracellular	NULL
free	NULL
calcium	NULL
(	NULL
[	NULL
Ca®*	NULL
]	NULL
,	NULL
;	NULL
)	NULL
(	NULL
reviewed	NULL
in	NULL
Clevers	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Finkel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

These	NULL
signals	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
phorbol	NULL
esters	NULL
which	NULL
activate	NULL
PKC	NULL
and	NULL
calcium	NULL
ionophores	NULL
(	NULL
Truneh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Macchia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

A	NULL
crucial	NULL
event	NULL
in	NULL
some	NULL
subsets	NULL
of	NULL
T-cells	NULL
is	NULL
the	NULL
induction	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
and	NULL
IL-2	NULL
receptor	NULL
(	NULL
IL-2R	NULL
)	NULL
expression	NULL
in	NULL
the	NULL
target	NULL
cells	NULL
.	NULL

Expression	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
results	NULL
in	NULL
autocrine	NULL
growth	NULL
stimulation	NULL
and	NULL
is	NULL
coincident	NULL
with	NULL
commitment	NULL
to	NULL
differentiation	NULL
.	NULL

The	NULL
signals	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
IL-2	NULL
expression	NULL
reflect	NULL
the	NULL
signals	NULL
required	NULL
for	NULL
T-cell	NULL
activation	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Crabtree	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

IL-2	NULL
expression	NULL
is	NULL
strictly	NULL
dependent	NULL
on	NULL
PKC	NULL
activity	NULL
and	NULL
calcium	NULL
mobilization	NULL
(	NULL
Macchia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
macrophage-derived	NULL
lymphokine	NULL
IL-1	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Dinarello	NULL
,	NULL
*	NULL
The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

{	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
39-577-293470	NULL
;	NULL
Fax	NULL
:	NULL
39-577-293564	NULL
.	NULL

'The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
TCR	NULL
,	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
R	NULL
,	NULL
receptor	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
.	NULL

1989	NULL
)	NULL
delivers	NULL
an	NULL
important	NULL
accessory	NULL
signal	NULL
capable	NULL
of	NULL
contributing	NULL
to	NULL
IL-2	NULL
activation	NULL
(	NULL
Abraham	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Macchia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

IL-2	NULL
expression	NULL
is	NULL
controlled	NULL
primarily	NULL
at	NULL
the	NULL
level	NULL
of	NULL
tran-scription	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
stimulation	NULL
,	NULL
the	NULL
promoter	NULL
is	NULL
virtually	NULL
inactive	NULL
(	NULL
reviewed	NULL
in	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
several	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
IL-2	NULL
gene	NULL
expression	NULL
,	NULL
AP-1	NULL
,	NULL
NF	NULL
«	NULL
B	NULL
,	NULL
and	NULL
NF-AT	NULL
are	NULL
known	NULL
to	NULL
respond	NULL
to	NULL
T-cell-activating	NULL
stimuli	NULL
.	NULL

NFkB	NULL
and	NULL
AP-1	NULL
are	NULL
stimulated	NULL
by	NULL
PKC	NULL
activity	NULL
and	NULL
respond	NULL
to	NULL
IL-1	NULL
but	NULL
do	NULL
not	NULL
respond	NULL
to	NULL
calcium	NULL
and	NULL
function	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
extracellular	NULL
calcium	NULL
(	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Muegge	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Serfling	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Espel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

NF-AT	NULL
,	NULL
however	NULL
,	NULL
requires	NULL
both	NULL
PKC	NULL
activity	NULL
and	NULL
calcium	NULL
mobilization	NULL
for	NULL
activation	NULL
,	NULL
which	NULL
may	NULL
explain	NULL
the	NULL
absolute	NULL
dependence	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
on	NULL
extracellular	NULL
calcium	NULL
.	NULL

The	NULL
NF-AT	NULL
transcription	NULL
factor	NULL
functions	NULL
as	NULL
a	NULL
heterodimer	NULL
.	NULL

In	NULL
the	NULL
human	NULL
lymphoma	NULL
cell	NULL
line	NULL
Jurkat	NULL
,	NULL
PKC	NULL
activation	NULL
results	NULL
in	NULL
induction	NULL
of	NULL
expression	NULL
of	NULL
a	NULL
nuclear	NULL
component	NULL
of	NULL
NF-AT	NULL
.	NULL

Increases	NULL
in	NULL
intracellular	NULL
free	NULL
calcium	NULL
result	NULL
in	NULL
translocation	NULL
of	NULL
a	NULL
second	NULL
,	NULL
constitutively	NULL
expressed	NULL
component	NULL
from	NULL
the	NULL
cytoplasm	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
an	NULL
active	NULL
complex	NULL
is	NULL
formed	NULL
(	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Recent	NULL
evidence	NULL
has	NULL
suggested	NULL
a	NULL
role	NULL
for	NULL
the	NULL
ras	NULL
family	NULL
of	NULL
small	NULL
GTP-binding	NULL
proteins	NULL
in	NULL
transduction	NULL
of	NULL
TCR	NULL
signals	NULL
.	NULL

First	NULL
,	NULL
Downward	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
TCR	NULL
triggering	NULL
or	NULL
PKC	NULL
activation	NULL
results	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
GTP-bound	NULL
active	NULL
form	NULL
of	NULL
ras	NULL
proteins	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
in	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

Second	NULL
,	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
a	NULL
constitutively	NULL
active	NULL
form	NULL
of	NULL
Ha-ras	NULL
expressed	NULL
in	NULL
the	NULL
murine	NULL
thymoma	NULL
line	NULL
,	NULL
EL4	NULL
,	NULL
can	NULL
replace	NULL
the	NULL
requirement	NULL
for	NULL
PKC	NULL
in	NULL
activation	NULL
in	NULL
IL-2	NULL
promoter	NULL
induction	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
expression	NULL
of	NULL
constitutively	NULL
active	NULL
Ha-ras	NULL
protein	NULL
can	NULL
replace	NULL
PKC	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
of	NULL
a	NULL
multimer	NULL
of	NULL
NF-AT	NULL
in	NULL
the	NULL
human	NULL
lymphoma	NULL
cell	NULL
line	NULL
Jurkat	NULL
.	NULL

We	NULL
show	NULL
that	NULL
TCR	NULL
induction	NULL
of	NULL
NF-AT	NULL
is	NULL
inhibited	NULL
by	NULL
expression	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
ras	NULL
protein	NULL
N17	NULL
(	NULL
Feig	NULL
and	NULL
Cooper	NULL
,	NULL
1988	NULL
)	NULL
indicating	NULL
that	NULL
ras	NULL
proteins	NULL
are	NULL
essential	NULL
for	NULL
TCR	NULL
signal	NULL
transduction	NULL
.	NULL

Interestingly	NULL
,	NULL
direct	NULL
stimulation	NULL
of	NULL
PKC	NULL
by	NULL
phorbol	NULL
ester	NULL
was	NULL
considerably	NULL
less	NULL
sensitive	NULL
to	NULL
N17	NULL
than	NULL
TCR	NULL
activation	NULL
,	NULL
suggesting	NULL
that	NULL
ras	NULL
proteins	NULL
may	NULL
function	NULL
both	NULL
upstream	NULL
and	NULL
downstream	NULL
of	NULL
PKC	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
an	NULL
inhibitor	NULL
of	NULL
PKC	NULL
activity	NULL
,	NULL
but	NULL
not	NULL
an	NULL
inhibitor	NULL
of	NULL
cyclic	NULL
nucleotide-dependent	NULL
kinases	NULL
,	NULL
blocked	NULL
oncogenic	NULL
ras	NULL
activation	NULL
of	NULL
NF-AT	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents-Recombinant	NULL
human	NULL
IL-18	NULL
from	NULL
Escherichia	NULL
coli	NULL
(	NULL
Cas-agli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
was	NULL
used	NULL
at	NULL
1	NULL
ng/ml	NULL
.	NULL

PMA	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
ionophore	NULL
A23187	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
were	NULL
dissolved	NULL
in	NULL
dimethyl	NULL
]	NULL
sulfoxide	NULL
at	NULL
100	NULL
ug/ml	NULL
and	NULL
10	NULL
mg/ml	NULL
,	NULL
respectively	NULL
.	NULL

PHA	NULL
(	NULL
Wellcome	NULL
Diagnos-tics	NULL
,	NULL
Dartford	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
was	NULL
dissolved	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
at	NULL
1	NULL
mg/ml	NULL
.	NULL

For	NULL
protein	NULL
determination	NULL
the	NULL
kit	NULL
BCA	NULL
from	NULL
Pierce	NULL
(	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
was	NULL
used	NULL
.	NULL

Acetyl	NULL
coenzyme	NULL
A	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
2693	NULL
2694	NULL
and	NULL
-	NULL
[	NULL
``	NULL
``	NULL
C	NULL
)	NULL
chloramphenicol	NULL
-	NULL
(	NULL
Amersham	NULL
_	NULL
International	NULL
,	NULL
-	NULL
United	NULL
Kingdom	NULL
)	NULL
were	NULL
used	NULL
for	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
assays	NULL
as	NULL
described	NULL
by	NULL
Gorman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
.	NULL

Restriction	NULL
and	NULL
modification	NULL
enzymes	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
and	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
were	NULL
used	NULL
according	NULL
to	NULL
the	NULL
manufacturers	NULL
'	NULL
instructions	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
determinations	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
Sequenase	NULL
kit	NULL
(	NULL
U.	NULL
S.	NULL
Biochemical	NULL
Co.	NULL
)	NULL
.	NULL

Polymerase	NULL
chain	NULL
reaction	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
a	NULL
Gene	NULL
Amp	NULL
kit	NULL
(	NULL
Perkin-Elmer	NULL
Cetus	NULL
Instruments	NULL
)	NULL
.	NULL

Oligonu-cleotides	NULL
were	NULL
synthesized	NULL
on	NULL
an	NULL
Applied	NULL
Biosystems	NULL
391	NULL
DNA	NULL
synthesizer	NULL
using	NULL
cyanoethyl	NULL
phosphoramidate	NULL
chemistry	NULL
.	NULL

Plasmids-IL-2/CAT	NULL
is	NULL
a	NULL
derivative	NULL
of	NULL
the	NULL
Bluescript	NULL
SK	NULL
plasmid	NULL
(	NULL
Stratagene	NULL
,	NULL
San	NULL
Diego	NULL
)	NULL
containing	NULL
a	NULL
2,000-base	NULL
pair	NULL
fragment	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
Macchia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

NF-AT/CAT	NULL
contains	NULL
a	NULL
trimer	NULL
of	NULL
the	NULL
NF-AT	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
pDOL~	NULL
expression	NULL
vector	NULL
has	NULL
been	NULL
described	NULL
elsewhere	NULL
(	NULL
Korman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

pSVT7/hIL-1R	NULL
has	NULL
been	NULL
described	NULL
elsewhere	NULL
(	NULL
Heguy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

T24-ras	NULL
containing	NULL
the	NULL
murine	NULL
leukemia	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
cloned	NULL
from	NULL
pDOL~	NULL
has	NULL
been	NULL
described	NULL
in	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
N17	NULL
inhibitory	NULL
mutant	NULL
(	NULL
Feig	NULL
and	NULL
Cooper	NULL
,	NULL
1988	NULL
)	NULL
was	NULL
generated	NULL
by	NULL
subcloning	NULL
the	NULL
Xbal	NULL
fragment	NULL
of	NULL
T24-ras	NULL
containing	NULL
the	NULL
first	NULL
exon	NULL
into	NULL
the	NULL
Xbal	NULL
cloning	NULL
site	NULL
of	NULL
pEMBL18	NULL
(	NULL
Dente	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
and	NULL
first	NULL
removing	NULL
the	NULL
activating	NULL
mutation	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
G	NULL
to	NULL
T	NULL
at	NULL
codon	NULL
12	NULL
(	NULL
valine	NULL
to	NULL
glycine	NULL
)	NULL
on	NULL
the	NULL
single-stranded	NULL
plasmid	NULL
as	NULL
described	NULL
(	NULL
Kunkel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

A	NULL
clone	NULL
containing	NULL
the	NULL
wild-type	NULL
sequence	NULL
identified	NULL
by	NULL
DNA	NULL
sequencing	NULL
was	NULL
then	NULL
used	NULL
for	NULL
a	NULL
second	NULL
round	NULL
of	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
G	NULL
to	NULL
A	NULL
at	NULL
position	NULL
17	NULL
(	NULL
serine	NULL
to	NULL
asparagine	NULL
)	NULL
.	NULL

The	NULL
Xbal	NULL
fragment	NULL
encoding	NULL
glycine	NULL
12	NULL
and	NULL
asparagine	NULL
17	NULL
was	NULL
finally	NULL
cloned	NULL
into	NULL
T24-ras	NULL
to	NULL
replace	NULL
the	NULL
original	NULL
homologous	NULL
fragment	NULL
.	NULL

Cell	NULL
Culture	NULL
,	NULL
Transfections	NULL
,	NULL
and	NULL
CAT	NULL
Assays-The	NULL
human	NULL
lymphoma	NULL
line	NULL
Jurkat	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
supplemented	NULL
with	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
20	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
and	NULL
10	NULL
%	NULL
heat-inactivated	NULL
(	NULL
56	NULL
°C	NULL
for	NULL
90	NULL
min	NULL
)	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

The	NULL
medium	NULL
used	NULL
for	NULL
transfections	NULL
included	NULL
200	NULL
units/ml	NULL
penicillin	NULL
(	NULL
Far-mitalia	NULL
,	NULL
Italy	NULL
)	NULL
.	NULL

Transfections	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
DEAE-dextran	NULL
procedure	NULL
as	NULL
described	NULL
(	NULL
Banerji	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
using	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
and	NULL
10-15	NULL
ug/sample	NULL
for	NULL
IL-2/CAT	NULL
transfections	NULL
or	NULL
1	NULL
x	NULL
10°	NULL
cells	NULL
and	NULL
1-2	NULL
ug	NULL
of	NULL
DNA/sample	NULL
for	NULL
NF-AT/CAT	NULL
transfections	NULL
.	NULL

To	NULL
avoid	NULL
error	NULL
caused	NULL
by	NULL
variation	NULL
in	NULL
transfection	NULL
efficiency	NULL
,	NULL
comparisons	NULL
of	NULL
stimuli	NULL
or	NULL
inhibitors	NULL
were	NULL
carried	NULL
out	NULL
on	NULL
identical	NULL
aliquots	NULL
of	NULL
single	NULL
pools	NULL
of	NULL
transfected	NULL
ceils	NULL
.	NULL

When	NULL
the	NULL
effect	NULL
of	NULL
T24	NULL
or	NULL
N17	NULL
was	NULL
tested	NULL
,	NULL
a	NULL
single	NULL
transfection	NULL
mix	NULL
was	NULL
prepared	NULL
containing	NULL
all	NULL
components	NULL
except	NULL
the	NULL
plasmid	NULL
to	NULL
be	NULL
tested	NULL
.	NULL

This	NULL
mixture	NULL
was	NULL
then	NULL
aliquoted	NULL
,	NULL
and	NULL
the	NULL
test	NULL
plasmid	NULL
or	NULL
an	NULL
appropriate	NULL
quantity	NULL
of	NULL
control	NULL
plasmid	NULL
was	NULL
added	NULL
.	NULL

Cells	NULL
were	NULL
allowed	NULL
to	NULL
recover	NULL
for	NULL
24	NULL
h	NULL
before	NULL
activation	NULL
.	NULL

The	NULL
PKC	NULL
inhibitor	NULL
H7	NULL
or	NULL
HA1004	NULL
(	NULL
Hidaka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
was	NULL
added	NULL
when	NULL
required	NULL
30	NULL
min	NULL
before	NULL
stimulation	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
8-10	NULL
h	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
,	NULL
resuspended	NULL
in	NULL
0.25	NULL
M	NULL
Tris	NULL
hydrochloride	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
and	NULL
extracted	NULL
by	NULL
freeze-thawing	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
proteins	NULL
,	NULL
determined	NULL
according	NULL
to	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Lowry	NULL
(	NULL
1951	NULL
)	NULL
,	NULL
were	NULL
used	NULL
for	NULL
CAT	NULL
assays	NULL
.	NULL

CAT	NULL
enzyme	NULL
activity	NULL
was	NULL
assayed	NULL
using	NULL
[	NULL
**C	NULL
)	NULL
chloramphenicol	NULL
according	NULL
to	NULL
Gorman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
.	NULL

Auto-radiographs	NULL
of	NULL
the	NULL
thin	NULL
layer	NULL
chromatograms	NULL
were	NULL
scanned	NULL
using	NULL
an	NULL
Ultrascan	NULL
XL	NULL
enhanced	NULL
laser	NULL
densitometer	NULL
.	NULL

RESULTS	NULL
The	NULL
human	NULL
lymphoma	NULL
cell	NULL
line	NULL
Jurkat	NULL
has	NULL
been	NULL
widely	NULL
used	NULL
to	NULL
study	NULL
IL-2	NULL
promoter	NULL
activation	NULL
by	NULL
mitogenic	NULL
stimuli	NULL
(	NULL
Fujita	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Siebenlist	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

A	NULL
reporter	NULL
construct	NULL
containing	NULL
the	NULL
bacterial	NULL
gene	NULL
for	NULL
CAT	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
IL-2/CAT	NULL
)	NULL
can	NULL
be	NULL
activated	NULL
in	NULL
Jurkat	NULL
cells	NULL
by	NULL
the	NULL
TCR	NULL
agonist	NULL
PHA	NULL
in	NULL
combination	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
PMA	NULL
(	NULL
>	NULL
10	NULL
ng/ml	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
and	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
)	NULL
.	NULL

Singly	NULL
these	NULL
stimuli	NULL
have	NULL
no	NULL
effect	NULL
.	NULL

In	NULL
addition	NULL
the	NULL
IL-2	NULL
promoter	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
the	NULL
calcium	NULL
ionophore	NULL
A23187	NULL
.	NULL

Treatment	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng/	NULL
ml	NULL
)	NULL
results	NULL
in	NULL
translocation	NULL
from	NULL
the	NULL
cytoplasm	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
consequent	NULL
activation	NULL
of	NULL
more	NULL
than	NULL
80	NULL
%	NULL
of	NULL
PKC	NULL
(	NULL
Nishizuka	NULL
,	NULL
1984	NULL
;	NULL
Berry	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

This	NULL
massive	NULL
PKC	NULL
2	NULL
C.	NULL
T.	NULL
Baldari	NULL
and	NULL
J.	NULL
L.	NULL
Telford	NULL
,	NULL
unpublished	NULL
results	NULL
.	NULL

ras	NULL
Mediates	NULL
TCR	NULL
Signal	NULL
Transduction	NULL
A	NULL
m	NULL
<	NULL
_	NULL
PH	NULL
_	NULL
PM	NULL
_	NULL
IL	NULL
PH	NULL
PH	NULL
-	NULL
PM	NULL
_	NULL
PM	NULL
IL	NULL
_	NULL
PM1	NULL
PMI	NULL
PM	NULL
IL	NULL
IL	NULL
_	NULL
A	NULL
A	NULL
A	NULL
_	NULL
A	NULL
IL	NULL
B	NULL
r	NULL
--	NULL
H-ras	NULL
--	NULL
@	NULL
»	NULL
«	NULL
»	NULL
dB	NULL
<	NULL
@	NULL
&	NULL
&	NULL
IL	NULL
__	NULL
PM	NULL
-	NULL
PH	NULL
IL	NULL
_	NULL
PM	NULL
-	NULL
PH	NULL
A	NULL
IL	NULL
_	NULL
PM	NULL
A	NULL
IL	NULL
__	NULL
PM	NULL
FiG	NULL
.	NULL

1	NULL
.	NULL

Activated	NULL
ras	NULL
expression	NULL
contributes	NULL
to	NULL
IL-2	NULL
promoter	NULL
activation	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
thin	NULL
layer	NULL
chromatogram	NULL
of	NULL
CAT	NULL
assays	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
10'/sample	NULL
)	NULL
cotransfected	NULL
with	NULL
the	NULL
plasmids	NULL
IL-2/	NULL
CAT	NULL
(	NULL
5	NULL
ug/sample	NULL
)	NULL
and	NULL
pSVT-hIL1R	NULL
(	NULL
5	NULL
ug/sample	NULL
)	NULL
and	NULL
activated	NULL
as	NULL
shown	NULL
below	NULL
each	NULL
lane	NULL
.	NULL

Relative	NULL
absorbance	NULL
of	NULL
acetylated	NULL
chloramphenicol	NULL
as	NULL
measured	NULL
by	NULL
laser	NULL
densitometry	NULL
:	NULL
PH/PM	NULL
,	NULL
0.96	NULL
;	NULL
PH/IL	NULL
,	NULL
0.46	NULL
;	NULL
PM/A	NULL
,	NULL
1.01	NULL
;	NULL
PM1/A	NULL
,	NULL
0.11	NULL
;	NULL
PM1/A/IL	NULL
,	NULL
0.64	NULL
;	NULL
all	NULL
other	NULL
treatments	NULL
were	NULL
below	NULL
detection	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
CAT	NULL
assays	NULL
of	NULL
Jurkat	NULL
cells	NULL
cotransfected	NULL
with	NULL
IL-2/CAT	NULL
(	NULL
4	NULL
ug/sample	NULL
)	NULL
,	NULL
pSVT/hIL1IR	NULL
(	NULL
3	NULL
ug/sample	NULL
)	NULL
,	NULL
and	NULL
either	NULL
the	NULL
plasmid	NULL
T24-ras	NULL
(	NULL
8	NULL
ug/sample	NULL
,	NULL
right	NULL
)	NULL
or	NULL
the	NULL
same	NULL
quantity	NULL
of	NULL
the	NULL
control	NULL
plasmid	NULL
pDOL~	NULL
(	NULL
left	NULL
)	NULL
.	NULL

Activations	NULL
are	NULL
shown	NULL
below	NULL
each	NULL
lane	NULL
.	NULL

Relative	NULL
absorbance	NULL
:	NULL
PH/PM	NULL
,	NULL
0.39	NULL
;	NULL
IL/A/H-ras	NULL
,	NULL
0.23	NULL
;	NULL
PH/PM/H-ras	NULL
,	NULL
0.29	NULL
;	NULL
all	NULL
others	NULL
were	NULL
below	NULL
detection	NULL
.	NULL

PH	NULL
,	NULL
1	NULL
ug/	NULL
ml	NULL
PHA	NULL
;	NULL
PM	NULL
,	NULL
10	NULL
ng/ml	NULL
PMA	NULL
;	NULL
PM1	NULL
,	NULL
1	NULL
ng/ml	NULL
PMA	NULL
;	NULL
IL	NULL
,	NULL
1	NULL
ng/ml	NULL
IL-18	NULL
;	NULL
A	NULL
,	NULL
100	NULL
ng/ml	NULL
A23187	NULL
.	NULL

The	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
several	NULL
experiments	NULL
.	NULL

activation	NULL
overcomes	NULL
the	NULL
requirement	NULL
for	NULL
accessory	NULL
signals	NULL
but	NULL
does	NULL
not	NULL
reflect	NULL
the	NULL
physiological	NULL
role	NULL
of	NULL
signals	NULL
such	NULL
as	NULL
IL-1	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
PKC	NULL
(	NULL
Abraham	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Macchia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
lack	NULL
IL-1	NULL
receptors	NULL
;	NULL
however	NULL
,	NULL
they	NULL
can	NULL
be	NULL
converted	NULL
to	NULL
IL-1	NULL
responsiveness	NULL
by	NULL
cotransfection	NULL
with	NULL
a	NULL
construct	NULL
capable	NULL
of	NULL
expressing	NULL
T-cell	NULL
type	NULL
IL-1	NULL
receptors	NULL
(	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Heguy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
the	NULL
IL-2/CAT	NULL
construct	NULL
responds	NULL
to	NULL
a	NULL
combination	NULL
of	NULL
TCR	NULL
stimulation	NULL
by	NULL
PHA	NULL
and	NULL
IL-1R	NULL
stimulation	NULL
by	NULL
IL-1	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

PHA	NULL
activation	NULL
of	NULL
the	NULL
TCR	NULL
results	NULL
in	NULL
a	NULL
low	NULL
level	NULL
activation	NULL
of	NULL
PKC	NULL
and	NULL
mobilization	NULL
of	NULL
calcium	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Berry	NULL
and	NULL
Nishizuka	NULL
(	NULL
1990	NULL
)	NULL
and	NULL
Gardner	NULL
(	NULL
1989	NULL
)	NULL
)	NULL
.	NULL

The	NULL
PHA	NULL
signal	NULL
can	NULL
therefore	NULL
best	NULL
be	NULL
mimicked	NULL
with	NULL
suboptimal	NULL
concentrations	NULL
of	NULL
PMA	NULL
(	NULL
<	NULL
1	NULL
ng/m	NULL
!	NULL

1	NULL
)	NULL
,	NULL
which	NULL
result	NULL
in	NULL
approximately	NULL
15	NULL
%	NULL
of	NULL
PKC	NULL
associated	NULL
with	NULL
the	NULL
membrane	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
plus	NULL
the	NULL
calcium	NULL
ionophore	NULL
A23187	NULL
.	NULL

This	NULL
combination	NULL
,	NULL
like	NULL
PHA	NULL
alone	NULL
,	NULL
had	NULL
very	NULL
little	NULL
effect	NULL
on	NULL
IL-2/CAT	NULL
activity	NULL
;	NULL
however	NULL
it	NULL
synergized	NULL
effectively	NULL
with	NULL
IL-1	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

Thus	NULL
in	NULL
this	NULL
model	NULL
of	NULL
T-cell	NULL
activation	NULL
the	NULL
three	NULL
signals	NULL
,	NULL
suboptimal	NULL
PKC	NULL
activation	NULL
,	NULL
calcium	NULL
mobilization	NULL
,	NULL
and	NULL
an	NULL
IL-1-induced	NULL
signal	NULL
,	NULL
are	NULL
required	NULL
for	NULL
IL-2	NULL
promoter	NULL
activation	NULL
.	NULL

Activated	NULL
ras	NULL
Protein	NULL
Replaces	NULL
PKC	NULL
Activation-T24	NULL
is	NULL
an	NULL
oncogenic	NULL
form	NULL
of	NULL
human	NULL
Ha-ras	NULL
which	NULL
is	NULL
activated	NULL
by	NULL
a	NULL
mutation	NULL
of	NULL
a	NULL
glycine	NULL
to	NULL
valine	NULL
at	NULL
position	NULL
12	NULL
(	NULL
Santos	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
results	NULL
in	NULL
reduced	NULL
GTPase	NULL
activity	NULL
and	NULL
accumulation	NULL
of	NULL
GTP-bound	NULL
active	NULL
ras	NULL
protein	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
IL-2/CAT	NULL
construct	NULL
in	NULL
Jurkat	NULL
cells	NULL
cotransfected	NULL
with	NULL
the	NULL
IL-1R	NULL
construct	NULL
,	NULL
and	NULL
a	NULL
construct	NULL
capable	NULL
of	NULL
expressing	NULL
T24-ras	NULL
(	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
no	NULL
longer	NULL
required	NULL
PMA	NULL
treatment	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
T24	NULL
,	NULL
treatment	NULL
with	NULL
IL-1	NULL
plus	NULL
A23187	NULL
,	NULL
which	NULL
in	NULL
control	NULL
cells	NULL
had	NULL
no	NULL
effect	NULL
,	NULL
resulted	NULL
in	NULL
significant	NULL
activation	NULL
of	NULL
IL-2/CAT	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
and	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

No	NULL
CAT	NULL
activity	NULL
was	NULL
detected	NULL
after	NULL
treatment	NULL
with	NULL
IL-1	NULL
alone	NULL
,	NULL
A23187	NULL
alone	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
IL-1	NULL
in	NULL
T24-cotransfected	NULL
cells	NULL
.	NULL

The	NULL
T24-ras	NULL
therefore	NULL
replaced	NULL
the	NULL
PMA	NULL
stimulus	NULL
but	NULL
the	NULL
not	NULL
the	NULL
ras	NULL
Mediates	NULL
TCR	NULL
Signal	NULL
Transduction	NULL
TABLE	NULL
I	NULL
Activation	NULL
of	NULL
IL-2/CAT	NULL
and	NULL
NF-AT/CAT	NULL
by	NULL
T24	NULL
IL-2/CAT	NULL
NF-AT/CAT	NULL
Treatment	NULL
-T24	NULL
+T24	NULL
-T24	NULL
+T24	NULL
IL-1	NULL
-*	NULL
-	NULL
-	NULL
PMA	NULL
«	NULL
-	NULL
-	NULL
-	NULL
A23187	NULL
-	NULL
-	NULL
-	NULL
0.42	NULL
PMA/A23187	NULL
ND®	NULL
ND	NULL
2.58	NULL
2.42	NULL
PMA/IL-1	NULL
-	NULL
IL-1/A23187	NULL
«	NULL
-	NULL
0.23	NULL
PHA/PMA	NULL
0.39	NULL
0.29	NULL
*	NULL
-	NULL
,	NULL
below	NULL
detection	NULL
.	NULL

°	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
in	NULL
this	NULL
experiment	NULL
.	NULL

A	NULL
«	NULL
ame	NULL
<	NULL
arame	NULL
«	NULL
ame	NULL
apr	NULL
@	NULL
r	NULL
@	NULL
@	NULL
@	NULL
-	NULL
&	NULL
@	NULL
a	NULL
PM	NULL
-	NULL
A	NULL
-	NULL
IL	NULL
PH	NULL
PM	NULL
PH	NULL
A	NULL
-	NULL
PM	NULL
IL	NULL
-	NULL
b	NULL
dL	NULL
A	NULL
B	NULL
r	NULL
--	NULL
H-ras	NULL
--	NULL
<	NULL
in	NULL
--	NULL
<	NULL
omm	NULL
L	NULL
J	NULL
am	NULL
»	NULL
am	NULL
»	NULL
am	NULL
»	NULL
cam	NULL
ca	NULL
«	NULL
ame	NULL
PM	NULL
-	NULL
A	NULL
-	NULL
PM	NULL
pm	NULL
-	NULL
A	NULL
-	NULL
pm	NULL
A	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Activated	NULL
ras	NULL
expression	NULL
contributes	NULL
to	NULL
NF-AT	NULL
activation	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
thin	NULL
layer	NULL
chromatogram	NULL
of	NULL
CAT	NULL
assays	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
10°/sample	NULL
)	NULL
cotransfected	NULL
with	NULL
the	NULL
plasmids	NULL
NF-AT/CAT	NULL
(	NULL
0.7	NULL
ug/sample	NULL
)	NULL
and	NULL
pSVT/hIL1R	NULL
(	NULL
0.5	NULL
ug/sample	NULL
)	NULL
and	NULL
activated	NULL
as	NULL
shown	NULL
below	NULL
each	NULL
lane	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
CAT	NULL
assays	NULL
of	NULL
Jurkat	NULL
cells	NULL
cotransfected	NULL
with	NULL
NF-AT/CAT	NULL
(	NULL
0.4	NULL
ug/sample	NULL
)	NULL
and	NULL
either	NULL
the	NULL
plasmid	NULL
T24-ras	NULL
(	NULL
1.2	NULL
ug/sample	NULL
,	NULL
right	NULL
)	NULL
or	NULL
the	NULL
control	NULL
plasmid	NULL
pDOL~	NULL
(	NULL
left	NULL
)	NULL
and	NULL
activated	NULL
as	NULL
shown	NULL
below	NULL
each	NULL
lane	NULL
.	NULL

PH	NULL
,	NULL
1	NULL
ug/ml	NULL
PHA	NULL
;	NULL
PM	NULL
,	NULL
10	NULL
ng/	NULL
ml	NULL
PMA	NULL
;	NULL
IL	NULL
,	NULL
1	NULL
ng/ml	NULL
IL-1	NULL
$	NULL
;	NULL
A	NULL
,	NULL
100	NULL
ng/ml	NULL
A23187	NULL
.	NULL

TABLE	NULL
II	NULL
Effect	NULL
of	NULL
quantity	NULL
of	NULL
NF-AT	NULL
transfected	NULL
Relative	NULL
absorbance	NULL
Treatment	NULL
0.3	NULL
ug	NULL
NF-AT	NULL
_	NULL
0.4	NULL
ag	NULL
NF-AT	NULL
_	NULL
0.7	NULL
ug	NULL
NF-AT	NULL
None	NULL
-*	NULL
-	NULL
PMA	NULL
-	NULL
-	NULL
«	NULL
-It	NULL
)	NULL
7	NULL
&	NULL
A23187	NULL
-	NULL
-	NULL
PHA	NULL
0.78	NULL
1.98	NULL
2.59	NULL
PHA/IL-1	NULL
ND®	NULL
2.89	NULL
3.05	NULL
PMA/IL-1	NULL
ND	NULL
-	NULL
IL-1/A23187	NULL
ND	NULL
-	NULL
PMA/A23187	NULL
2.44	NULL
2.93	NULL
2.171	NULL
*	NULL
-	NULL
,	NULL
below	NULL
detection	NULL
.	NULL

°	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

calcium-mediated	NULL
signal	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
constitutively	NULL
active	NULL
ras	NULL
can	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
replace	NULL
the	NULL
PKC-activating	NULL
component	NULL
of	NULL
TCR	NULL
signaling	NULL
.	NULL

ras	NULL
Activation	NULL
of	NULL
IL-2	NULL
Expression	NULL
Is	NULL
Mediated	NULL
by	NULL
NF-AT	NULL
TCR	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
is	NULL
mediated	NULL
by	NULL
two	NULL
short	NULL
nucleotide	NULL
sequences	NULL
known	NULL
as	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

One	NULL
of	NULL
these	NULL
sequences	NULL
binds	NULL
the	NULL
activated	NULL
T-cell-specific	NULL
transcription	NULL
factor	NULL
,	NULL
NF-AT	NULL
(	NULL
Shaw	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

As	NULL
was	NULL
reported	NULL
previously	NULL
(	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
a	NULL
construct	NULL
containing	NULL
the	NULL
CAT	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
synthetic	NULL
promoter	NULL
containing	NULL
several	NULL
copies	NULL
of	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
NF-AT	NULL
was	NULL
activated	NULL
by	NULL
PHA	NULL
alone	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
A23187	NULL
(	NULL
Fig	NULL
.	NULL

24A	NULL
and	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

No	NULL
2695	NULL
accessory	NULL
signals	NULL
were	NULL
required	NULL
,	NULL
and	NULL
PMA	NULL
alone	NULL
or	NULL
A23187	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

In	NULL
cells	NULL
cotransfected	NULL
with	NULL
the	NULL
IL-1R	NULL
construct	NULL
,	NULL
IL-1	NULL
treatment	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
PMA	NULL
or	NULL
A23187	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
NF-AT/CAT	NULL
activity	NULL
;	NULL
however	NULL
,	NULL
PHA	NULL
stimulation	NULL
was	NULL
somewhat	NULL
enhanced	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
and	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

The	NULL
NF-AT	NULL
factor	NULL
therefore	NULL
responds	NULL
to	NULL
TCR	NULL
triggering	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
accessory	NULL
signals	NULL
.	NULL

Presumably	NULL
,	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
,	NULL
NF-AT	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
mediate	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
TCR	NULL
signals	NULL
.	NULL

Cotransfection	NULL
of	NULL
NF-AT/CAT	NULL
with	NULL
the	NULL
T24	NULL
construct	NULL
in	NULL
part	NULL
obviated	NULL
the	NULL
need	NULL
for	NULL
PMA	NULL
treatment	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
T24-ras	NULL
,	NULL
A23187	NULL
alone	NULL
induced	NULL
significant	NULL
CAT	NULL
activity	NULL
,	NULL
whereas	NULL
PMA	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
and	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
T24-ras	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
mediated	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
by	NULL
NF-AT	NULL
.	NULL

ras	NULL
Activity	NULL
Is	NULL
Necessary	NULL
for	NULL
TCR	NULL
Signaling-The	NULL
data	NULL
presented	NULL
so	NULL
far	NULL
show	NULL
that	NULL
activated	NULL
ras	NULL
can	NULL
replace	NULL
PKC	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
NF-AT	NULL
.	NULL

To	NULL
address	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
ras	NULL
proteins	NULL
play	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
TCR	NULL
signal	NULL
transduction	NULL
we	NULL
have	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
inhibition	NULL
of	NULL
endogenous	NULL
ras	NULL
activity	NULL
on	NULL
PHA	NULL
induction	NULL
of	NULL
NF-AT/CAT	NULL
.	NULL

A	NULL
single	NULL
amino	NULL
acid	NULL
substitution	NULL
from	NULL
serine	NULL
to	NULL
asparagine	NULL
at	NULL
position	NULL
17	NULL
in	NULL
the	NULL
ras	NULL
protein	NULL
not	NULL
only	NULL
inactivates	NULL
the	NULL
protein	NULL
but	NULL
also	NULL
results	NULL
in	NULL
a	NULL
molecule	NULL
capable	NULL
of	NULL
inhibiting	NULL
wild	NULL
type	NULL
ras	NULL
function	NULL
(	NULL
Feig	NULL
and	NULL
Cooper	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
mutation	NULL
interferes	NULL
with	NULL
GTP-GDP	NULL
exchange	NULL
,	NULL
and	NULL
thus	NULL
the	NULL
mutated	NULL
protein	NULL
does	NULL
not	NULL
inhibit	NULL
oncogenic	NULL
ras	NULL
activity	NULL
(	NULL
Medema	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Stacey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Using	NULL
site-directed	NULL
mutagenesis	NULL
we	NULL
have	NULL
modified	NULL
the	NULL
T24	NULL
construct	NULL
to	NULL
remove	NULL
the	NULL
Val'®-activating	NULL
mutation	NULL
and	NULL
to	NULL
introduce	NULL
the	NULL
Asn	NULL
``	NULL
mutation	NULL
.	NULL

This	NULL
construct	NULL
(	NULL
N17	NULL
)	NULL
was	NULL
cotransfected	NULL
with	NULL
the	NULL
NF-AT	NULL
construct	NULL
into	NULL
Jurkat	NULL
cells	NULL
which	NULL
were	NULL
subsequently	NULL
treated	NULL
with	NULL
either	NULL
PHA	NULL
or	NULL
PMA	NULL
plus	NULL
A23187	NULL
.	NULL

The	NULL
results	NULL
of	NULL
an	NULL
experiment	NULL
in	NULL
which	NULL
aliquots	NULL
of	NULL
a	NULL
single	NULL
pool	NULL
of	NULL
competent	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
fixed	NULL
amount	NULL
of	NULL
reporter	NULL
plasmid	NULL
and	NULL
varying	NULL
amounts	NULL
of	NULL
N17	NULL
DNA	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

At	NULL
ratios	NULL
of	NULL
0.5	NULL
ug	NULL
or	NULL
1	NULL
ug	NULL
of	NULL
N17	NULL
DNA	NULL
to	NULL
A	NULL
N17	NULL
f	NULL
f	NULL
as	NULL
ager	NULL
-4	NULL
0	NULL
0.5	NULL
1.0	NULL
1.5	NULL
w.	NULL
eti	NULL
«	NULL
omg	NULL
hvad	NULL
PH	NULL
-	NULL
PM	NULL
PH	NULL
PM	NULL
PH	NULL
PM	NULL
PH	NULL
-	NULL
PM	NULL
A	NULL
A	NULL
A	NULL
A	NULL
N17	NULL
-H-ras	NULL
PH	NULL
-	NULL
PM	NULL
-	NULL
PH	NULL
-	NULL
PM	NULL
A	NULL
A	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

The	NULL
dominant	NULL
negative	NULL
ras	NULL
mutant	NULL
N17	NULL
blocks	NULL
TCR-induced	NULL
activation	NULL
of	NULL
NF-AT	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
thin	NULL
layer	NULL
chromatogram	NULL
of	NULL
CAT	NULL
assays	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
10°/sample	NULL
)	NULL
cotransfected	NULL
with	NULL
the	NULL
plasmid	NULL
NF-AT/CAT	NULL
(	NULL
0.3	NULL
ug/sample	NULL
)	NULL
and	NULL
increasing	NULL
amounts	NULL
of	NULL
N17	NULL
DNA	NULL
as	NULL
indicated	NULL
above	NULL
the	NULL
lames	NULL
(	NULL
ug	NULL
of	NULL
DNA/sample	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
expression	NULL
plasmid/sample	NULL
were	NULL
maintained	NULL
by	NULL
using	NULL
the	NULL
appropriate	NULL
quantity	NULL
of	NULL
pDOL~	NULL
in	NULL
addition	NULL
to	NULL
N17	NULL
.	NULL

Cells	NULL
were	NULL
activated	NULL
as	NULL
shown	NULL
below	NULL
each	NULL
lane	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
CAT	NULL
assays	NULL
of	NULL
Jurkat	NULL
cells	NULL
cotransfected	NULL
with	NULL
NF-AT/CAT	NULL
(	NULL
0.4	NULL
ug/sample	NULL
)	NULL
,	NULL
N17	NULL
(	NULL
0.7	NULL
ug/sample	NULL
)	NULL
,	NULL
and	NULL
either	NULL
T24-ras	NULL
(	NULL
0.5	NULL
ug	NULL
)	NULL
or	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
pDOL~	NULL
.	NULL

Cells	NULL
were	NULL
activated	NULL
as	NULL
indicated	NULL
below	NULL
each	NULL
lane	NULL
.	NULL

PH	NULL
,	NULL
1	NULL
ug/ml	NULL
PHA	NULL
;	NULL
PM	NULL
,	NULL
10	NULL
ng/ml	NULL
PMA	NULL
;	NULL
A	NULL
,	NULL
100	NULL
ng/ml	NULL
A23187	NULL
.	NULL

2696	NULL
10°	NULL
cells	NULL
,	NULL
CAT	NULL
activity	NULL
obtained	NULL
on	NULL
activation	NULL
with	NULL
PHA	NULL
was	NULL
significantly	NULL
reduced	NULL
,	NULL
while	NULL
PMA/A23187-induced	NULL
CAT	NULL
activity	NULL
was	NULL
not	NULL
affected	NULL
.	NULL

1.5	NULL
ug	NULL
of	NULL
N17	NULL
DNA	NULL
resulted	NULL
in	NULL
reduction	NULL
of	NULL
both	NULL
the	NULL
PHA-	NULL
and	NULL
the	NULL
PMA/A23187-induced	NULL
CAT	NULL
activity	NULL
.	NULL

Table	NULL
III	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
laser	NULL
densitometry	NULL
of	NULL
thin	NULL
layer	NULL
chromatograms	NULL
from	NULL
several	NULL
experiments	NULL
.	NULL

In	NULL
all	NULL
experiments	NULL
,	NULL
PHA	NULL
induction	NULL
was	NULL
considerably	NULL
more	NULL
sensitive	NULL
to	NULL
N17	NULL
than	NULL
was	NULL
PMA/A23187	NULL
induction	NULL
.	NULL

When	NULL
different	NULL
experiments	NULL
were	NULL
compared	NULL
,	NULL
transfection	NULL
efficiency	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
CAT	NULL
activity	NULL
in	NULL
a	NULL
control	NULL
sample	NULL
,	NULL
had	NULL
a	NULL
greater	NULL
influence	NULL
on	NULL
N17	NULL
efficacy	NULL
than	NULL
the	NULL
amount	NULL
of	NULL
DNA	NULL
used	NULL
.	NULL

Thus	NULL
when	NULL
transfection	NULL
was	NULL
more	NULL
efficient	NULL
,	NULL
a	NULL
greater	NULL
inhibition	NULL
of	NULL
both	NULL
PHA	NULL
and	NULL
PMA/A23187	NULL
stimulation	NULL
was	NULL
observed	NULL
(	NULL
see	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
N17	NULL
protein	NULL
expressed	NULL
and	NULL
consequently	NULL
its	NULL
ability	NULL
to	NULL
inhibit	NULL
endogenous	NULL
ras	NULL
proteins	NULL
presumably	NULL
depend	NULL
on	NULL
the	NULL
amount	NULL
of	NULL
N17	NULL
DNA	NULL
taken	NULL
up	NULL
by	NULL
the	NULL
cells	NULL
.	NULL

Coexpression	NULL
of	NULL
T24-ras	NULL
with	NULL
N17	NULL
overcame	NULL
the	NULL
reduction	NULL
of	NULL
the	NULL
PHA	NULL
signal	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
the	NULL
N17	NULL
effect	NULL
is	NULL
caused	NULL
by	NULL
inhibition	NULL
of	NULL
ras	NULL
proteins	NULL
and	NULL
not	NULL
by	NULL
any	NULL
nonspe-cific	NULL
effects	NULL
of	NULL
the	NULL
N17	NULL
DNA	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
by	NULL
comparison	NULL
of	NULL
Fig	NULL
.	NULL

24	NULL
with	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
the	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
induced	NULL
by	NULL
PHA	NULL
compared	NULL
with	NULL
PMA/	NULL
A23187	NULL
was	NULL
significantly	NULL
less	NULL
when	NULL
lower	NULL
amounts	NULL
(	NULL
0.3	NULL
ug/	NULL
10°	NULL
cells	NULL
)	NULL
of	NULL
the	NULL
NF-AT/CAT	NULL
plasmid	NULL
were	NULL
used	NULL
in	NULL
the	NULL
transfections	NULL
,	NULL
suggesting	NULL
that	NULL
at	NULL
the	NULL
higher	NULL
concentration	NULL
(	NULL
0.7	NULL
ug/	NULL
10°	NULL
cells	NULL
)	NULL
CAT	NULL
activity	NULL
was	NULL
reaching	NULL
saturation	NULL
in	NULL
this	NULL
system	NULL
(	NULL
see	NULL
also	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Thus	NULL
at	NULL
lower	NULL
doses	NULL
of	NULL
reporter	NULL
gene	NULL
PHA	NULL
delivers	NULL
a	NULL
weaker	NULL
signal	NULL
than	NULL
PMA/A23187	NULL
,	NULL
which	NULL
may	NULL
explain	NULL
the	NULL
difference	NULL
in	NULL
sensitivity	NULL
to	NULL
N17	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
shows	NULL
the	NULL
effect	NULL
of	NULL
N17	NULL
transfection	NULL
on	NULL
activation	NULL
of	NULL
NF-AT/CAT	NULL
by	NULL
suboptimal	NULL
PMA	NULL
(	NULL
1	NULL
ng/ml	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
A23187	NULL
compared	NULL
with	NULL
its	NULL
effect	NULL
on	NULL
PHA	NULL
or	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
A23187	NULL
.	NULL

No	NULL
significant	NULL
difference	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
sensitivity	NULL
of	NULL
PHA	NULL
or	NULL
suboptimal	NULL
PMA/A23187	NULL
to	NULL
N17	NULL
,	NULL
whereas	NULL
optimal	NULL
PMA/A23187	NULL
was	NULL
less	NULL
sensitive	NULL
.	NULL

The	NULL
results	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
IV	NULL
.	NULL

The	NULL
preceding	NULL
experiments	NULL
indicate	NULL
that	NULL
ras	NULL
activity	NULL
is	NULL
essential	NULL
for	NULL
TCR	NULL
signaling	NULL
.	NULL

Maximal	NULL
stimulation	NULL
of	NULL
PKC	NULL
with	NULL
PMA	NULL
was	NULL
less	NULL
sensitive	NULL
to	NULL
inhibition	NULL
by	NULL
N17	NULL
than	NULL
PHA	NULL
stimulation	NULL
.	NULL

This	NULL
may	NULL
simply	NULL
reflect	NULL
the	NULL
difference	NULL
in	NULL
strength	NULL
of	NULL
the	NULL
stimulations	NULL
;	NULL
however	NULL
,	NULL
it	NULL
may	NULL
indicate	NULL
a	NULL
role	NULL
for	NULL
ras	NULL
proteins	NULL
upstream	NULL
of	NULL
PKC	NULL
,	NULL
inhibition	NULL
of	NULL
which	NULL
could	NULL
be	NULL
overcome	NULL
by	NULL
sufficient	NULL
direct	NULL
stimulation	NULL
of	NULL
PKC	NULL
by	NULL
PMA	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
,	NULL
H7	NULL
,	NULL
an	NULL
isoquinoline	NULL
sulfonamide	NULL
which	NULL
blocks	NULL
PKC	NULL
and	NULL
cyclic	NULL
nucleotide-dependent	NULL
protein	NULL
kinases	NULL
(	NULL
Hidaka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
,	NULL
completely	NULL
blocked	NULL
activation	NULL
of	NULL
NF-	NULL
TABLE	NULL
III	NULL
Effect	NULL
of	NULL
N17	NULL
on	NULL
NF-AT/CAT	NULL
activation	NULL
by	NULL
PHA	NULL
or	NULL
PMA/A23187	NULL
(	NULL
PMA/A	NULL
)	NULL
Reduction	NULL
of	NULL
CAT	NULL
g	NULL
feet	NULL
activit	NULL
ransfection	NULL
N17	NULL
DNA/10®	NULL
cells	NULL
efficiency*	NULL
PHA	NULL
PMA/A	NULL
%	NULL
%	NULL
%	NULL
Expt	NULL
.	NULL

1°	NULL
0.5	NULL
ug	NULL
63	NULL
0	NULL
21	NULL
.	NULL

1.0	NULL
ug	NULL
55	NULL
0	NULL
23	NULL
1.5	NULL
ug	NULL
68	NULL
32	NULL
23	NULL
Expt	NULL
.	NULL

2	NULL
0.7	NULL
ug	NULL
81	NULL
51	NULL
t	NULL
Expt	NULL
.	NULL

3	NULL
0.9	NULL
ug	NULL
58	NULL
30	NULL
§3	NULL
Expt	NULL
.	NULL

4	NULL
1.3	NULL
ug	NULL
51	NULL
0	NULL
85	NULL
*	NULL
Percent	NULL
of	NULL
chloramphenicol	NULL
conversion	NULL
in	NULL
the	NULL
control	NULL
sample	NULL
.	NULL

®	NULL
Experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3.	NULL
ras	NULL
Mediates	NULL
TCR	NULL
Signal	NULL
Transduction	NULL
1,0	NULL
7	NULL
m	NULL
-o	NULL
A	NULL
0,4ug	NULL
N17	NULL
os	NULL
{	NULL
-	NULL
@	NULL
0,8ug	NULL
N17	NULL
0,6	NULL
7	NULL
absorbance	NULL
0,4	NULL
7	NULL
0,2	NULL
7	NULL
sss	NULL
hs	NULL
ees	NULL
}	NULL
0,0	NULL
9	NULL
PHA	NULL
PM1/A	NULL
PM10/A	NULL
FiG	NULL
.	NULL

4	NULL
.	NULL

Effect	NULL
of	NULL
N17	NULL
on	NULL
suboptimal	NULL
activation	NULL
of	NULL
NF-AT	NULL
.	NULL

Relative	NULL
absorbances	NULL
of	NULL
acetylated	NULL
[	NULL
``	NULL
``	NULL
C	NULL
)	NULL
chloramphenicol	NULL
in	NULL
autora-	NULL
diograms	NULL
of	NULL
CAT	NULL
assays	NULL
of	NULL
Jurkat	NULL
cells	NULL
cotransfected	NULL
with	NULL
NF-AT/	NULL
CAT	NULL
(	NULL
0.4	NULL
ug/sample	NULL
)	NULL
and	NULL
either	NULL
N17	NULL
(	NULL
0	NULL
,	NULL
0.4	NULL
,	NULL
or	NULL
0.8	NULL
ug/sample	NULL
as	NULL
shown	NULL
)	NULL
or	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
pDOL~	NULL
and	NULL
activated	NULL
as	NULL
shown	NULL
above	NULL
each	NULL
column	NULL
.	NULL

PHA	NULL
,	NULL
1	NULL
ug/ml	NULL
PHA	NULL
;	NULL
PMA1	NULL
,	NULL
1	NULL
ng/ml	NULL
PMA	NULL
;	NULL
PMA1O	NULL
,	NULL
10	NULL
ng/ml	NULL
PMA	NULL
;	NULL
A	NULL
,	NULL
100	NULL
ng/ml	NULL
A23187	NULL
.	NULL

TABLE	NULL
IV	NULL
Effect	NULL
of	NULL
N17	NULL
on	NULL
NF-AT	NULL
activation	NULL
by	NULL
suboptimal	NULL
PMA	NULL
PM1	NULL
,	NULL
1	NULL
ng/ml	NULL
PMA	NULL
;	NULL
A	NULL
,	NULL
100	NULL
ng/ml	NULL
A23187	NULL
.	NULL

§	NULL
Expt	NULL
.	NULL

1	NULL
Expt	NULL
.	NULL

2	NULL
Expt	NULL
.	NULL

3	NULL
17	NULL
PHA	NULL
PM1/A	NULL
PHA	NULL
PM1/A	NULL
PHA	NULL
PM1/A	NULL
L8	NULL
0	NULL
0.28	NULL
0.45	NULL
0.23	NULL
0.16	NULL
0.55	NULL
0.51	NULL
0.4	NULL
0.25	NULL
0.45	NULL
0.17	NULL
0.08	NULL
0.52	NULL
0.46	NULL
0.8	NULL
0.17	NULL
0.32	NULL
0.09	NULL
0.04	NULL
0.40	NULL
0.24	NULL
H-ras	NULL
H7	NULL
r-	NULL
H7	NULL
--	NULL
r	NULL
HA10O04	NULL
<	NULL
smm	NULL
fr	NULL
x	NULL
3	NULL
@	NULL
<	NULL
m	NULL
<	NULL
»	NULL
<	NULL
o	NULL
--	NULL
»	NULL
a	NULL
>	NULL
a	NULL
»	NULL
as	NULL
a	NULL
»	NULL
&	NULL
A	NULL
-	NULL
PM	NULL
PM	NULL
A	NULL
-	NULL
PM	NULL
_	NULL
A	NULL
_	NULL
PM	NULL
A	NULL
-	NULL
PM	NULL
A	NULL
_	NULL
A	NULL
A	NULL
A	NULL
A	NULL
Fic	NULL
.	NULL

5.	NULL
ras	NULL
activation	NULL
of	NULL
NF-AT	NULL
is	NULL
blocked	NULL
by	NULL
the	NULL
PKC	NULL
inhibitor	NULL
H7	NULL
.	NULL

Thin	NULL
layer	NULL
chromatogram	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
10°/sample	NULL
)	NULL
cotransfected	NULL
with	NULL
NF-AT/CAT	NULL
(	NULL
0.5	NULL
ug/sample	NULL
)	NULL
and	NULL
either	NULL
T24-ras	NULL
(	NULL
1.1	NULL
ug/sample	NULL
,	NULL
right	NULL
)	NULL
or	NULL
the	NULL
control	NULL
plasmid	NULL
pDOL~	NULL
(	NULL
left	NULL
)	NULL
and	NULL
activated	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
H7	NULL
(	NULL
20	NULL
um	NULL
)	NULL
or	NULL
HA1004	NULL
(	NULL
50	NULL
um	NULL
)	NULL
.	NULL

PH	NULL
,	NULL
1	NULL
ug/ml	NULL
PHA	NULL
;	NULL
PM	NULL
,	NULL
10	NULL
ng/ml	NULL
PMA	NULL
;	NULL
A	NULL
,	NULL
100	NULL
ng/ml	NULL
A23187	NULL
.	NULL

AT/CAT	NULL
by	NULL
T24/A23187	NULL
,	NULL
whereas	NULL
HA1004	NULL
,	NULL
a	NULL
similar	NULL
compound	NULL
which	NULL
blocks	NULL
preferentially	NULL
cyclic	NULL
nucleotide-dependent	NULL
kinases	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Ha-ras	NULL
may	NULL
therefore	NULL
function	NULL
upstream	NULL
of	NULL
PKC	NULL
.	NULL

DISCUSSION	NULL
A	NULL
role	NULL
for	NULL
ras	NULL
proteins	NULL
in	NULL
the	NULL
transduction	NULL
of	NULL
extracellular	NULL
signals	NULL
has	NULL
long	NULL
been	NULL
suggested	NULL
by	NULL
their	NULL
structural	NULL
similarity	NULL
to	NULL
the	NULL
trimeric	NULL
(	NULL
G-nucleotide-binding	NULL
proteins	NULL
,	NULL
their	NULL
location	NULL
on	NULL
the	NULL
inner	NULL
flap	NULL
of	NULL
the	NULL
plasma	NULL
membrane	NULL
,	NULL
and	NULL
their	NULL
role	NULL
in	NULL
oncogenesis	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Barbacid	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

This	NULL
view	NULL
has	NULL
been	NULL
considerably	NULL
strengthened	NULL
by	NULL
reports	NULL
of	NULL
ras	NULL
involvement	NULL
in	NULL
nerve	NULL
growth	NULL
factor-induced	NULL
phosphorylation	NULL
of	NULL
MAP	NULL
ras	NULL
Mediates	NULL
TCR	NULL
Signal	NULL
Transduction	NULL
kinases	NULL
(	NULL
Wood	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
and	NULL
insulin-induced	NULL
gene	NULL
expression	NULL
(	NULL
Medema	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

A	NULL
role	NULL
for	NULL
ras	NULL
in	NULL
TCR	NULL
signal	NULL
transduction	NULL
was	NULL
suggested	NULL
by	NULL
reports	NULL
that	NULL
TCR	NULL
engagement	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
active	NULL
GTP-bound	NULL
form	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
Downward	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
and	NULL
that	NULL
a	NULL
constitutively	NULL
active	NULL
ras	NULL
mutant	NULL
in	NULL
ELA	NULL
cells	NULL
could	NULL
contribute	NULL
part	NULL
of	NULL
the	NULL
signals	NULL
necessary	NULL
for	NULL
IL-2	NULL
gene	NULL
activation	NULL
(	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

We	NULL
have	NULL
used	NULL
Jurkat	NULL
cells	NULL
as	NULL
a	NULL
model	NULL
system	NULL
to	NULL
analyze	NULL
further	NULL
the	NULL
role	NULL
of	NULL
ras	NULL
in	NULL
mediating	NULL
the	NULL
TCR-derived	NULL
signals	NULL
and	NULL
show	NULL
a	NULL
direct	NULL
involvement	NULL
of	NULL
ras	NULL
proteins	NULL
in	NULL
transduction	NULL
of	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
TCR	NULL
signals	NULL
which	NULL
lead	NULL
to	NULL
activation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
.	NULL

TCR	NULL
engagement	NULL
results	NULL
in	NULL
phosphatidylinositol	NULL
metabolism	NULL
to	NULL
produce	NULL
inositol	NULL
triphosphate	NULL
and	NULL
diacylglycerol	NULL
.	NULL

Inositol	NULL
triphosphate	NULL
causes	NULL
a	NULL
transient	NULL
increase	NULL
in	NULL
intracellular	NULL
free	NULL
calcium	NULL
,	NULL
and	NULL
diacylglycerol	NULL
activates	NULL
PKC	NULL
.	NULL

A	NULL
further	NULL
sustained	NULL
increase	NULL
in	NULL
calcium	NULL
from	NULL
extracellular	NULL
stores	NULL
is	NULL
mediated	NULL
by	NULL
an	NULL
as	NULL
yet	NULL
poorly	NULL
understood	NULL
mechanism	NULL
(	NULL
reviewed	NULL
in	NULL
Crabtree	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Finkel	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
,	NULL
Truneh	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
)	NULL
.	NULL

These	NULL
two	NULL
signals	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
directly	NULL
activating	NULL
PKC	NULL
with	NULL
phorbol	NULL
esters	NULL
and	NULL
by	NULL
increasing	NULL
intracellular	NULL
free	NULL
calcium	NULL
by	NULL
means	NULL
of	NULL
calcium	NULL
ionophores	NULL
.	NULL

In	NULL
this	NULL
work	NULL
we	NULL
have	NULL
used	NULL
a	NULL
combination	NULL
of	NULL
suboptimal	NULL
concentrations	NULL
of	NULL
PMA	NULL
and	NULL
a	NULL
calcium	NULL
ionophore	NULL
which	NULL
,	NULL
like	NULL
TCR	NULL
engagement	NULL
,	NULL
have	NULL
little	NULL
effect	NULL
on	NULL
IL-2	NULL
expression	NULL
but	NULL
which	NULL
synergize	NULL
effectively	NULL
with	NULL
the	NULL
macrophage-derived	NULL
lymphocyte-activat-ing	NULL
factor	NULL
IL-1	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
constitutively	NULL
active	NULL
ras	NULL
oncoprotein	NULL
can	NULL
substitute	NULL
for	NULL
suboptimal	NULL
PKC	NULL
activation	NULL
but	NULL
not	NULL
for	NULL
IL-1	NULL
or	NULL
calcium-mediated	NULL
signals	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
pro-moter	NULL
.	NULL

In	NULL
addition	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
NF-AT	NULL
transcription	NULL
factor	NULL
mediates	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
this	NULL
effect	NULL
.	NULL

A	NULL
dominant	NULL
negative	NULL
ras	NULL
mutant	NULL
reduced	NULL
NF-AT	NULL
activation	NULL
,	NULL
indicating	NULL
that	NULL
ras	NULL
proteins	NULL
are	NULL
essential	NULL
for	NULL
TCR	NULL
signaling	NULL
.	NULL

N17	NULL
inhibited	NULL
TCR	NULL
signaling	NULL
under	NULL
conditions	NULL
which	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
direct	NULL
activation	NULL
of	NULL
PKC	NULL
by	NULL
saturating	NULL
concentrations	NULL
of	NULL
phorbol	NULL
esters	NULL
.	NULL

This	NULL
and	NULL
the	NULL
fact	NULL
that	NULL
an	NULL
inhibitor	NULL
of	NULL
PKC	NULL
blocked	NULL
NF-AT	NULL
activation	NULL
by	NULL
constitutively	NULL
active	NULL
Ha-ras	NULL
indicate	NULL
that	NULL
ras	NULL
protein	NULL
functions	NULL
upstream	NULL
of	NULL
PKC	NULL
.	NULL

This	NULL
interpretation	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
other	NULL
reports	NULL
that	NULL
oncogenic	NULL
ras	NULL
mutants	NULL
result	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
diacylglycerol	NULL
,	NULL
a	NULL
physiological	NULL
activator	NULL
of	NULL
PKC	NULL
(	NULL
Wolfman	NULL
and	NULL
Macara	NULL
,	NULL
1987	NULL
;	NULL
Price	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
and	NULL
that	NULL
down-regulation	NULL
of	NULL
PKC	NULL
abrogates	NULL
oncogenic	NULL
ras-induced	NULL
mitogenesis	NULL
of	NULL
Swiss	NULL
3T3	NULL
fibroblasts	NULL
(	NULL
Lacal	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Downward	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
both	NULL
TCR	NULL
engagement	NULL
and	NULL
phorbol	NULL
esters	NULL
cause	NULL
an	NULL
increase	NULL
in	NULL
GTP-bound	NULL
ras	NULL
protein	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
phorbol	NULL
ester	NULL
stimulation	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
MAP	NULL
kinases	NULL
is	NULL
inhibited	NULL
by	NULL
N17	NULL
ras	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Wood	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
these	NULL
data	NULL
the	NULL
authors	NULL
suggest	NULL
that	NULL
PKC	NULL
activates	NULL
ras	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
others	NULL
(	NULL
Leevers	NULL
and	NULL
Marshall	NULL
,	NULL
1992	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
oncogenic	NULL
ras	NULL
activation	NULL
of	NULL
MAP	NULL
kinases	NULL
is	NULL
abrogated	NULL
by	NULL
down-regulation	NULL
of	NULL
PKC	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
inhibition	NULL
of	NULL
optimal	NULL
PMA	NULL
stimulation	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
N17	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
suboptimal	NULL
concentrations	NULL
of	NULL
PMA	NULL
were	NULL
as	NULL
sensitive	NULL
to	NULL
N17	NULL
as	NULL
PHA	NULL
stimulation	NULL
.	NULL

One	NULL
possible	NULL
explanation	NULL
of	NULL
these	NULL
apparently	NULL
contrasting	NULL
results	NULL
is	NULL
that	NULL
ras	NULL
proteins	NULL
play	NULL
a	NULL
role	NULL
both	NULL
upstream	NULL
and	NULL
downstream	NULL
of	NULL
PKC	NULL
.	NULL

Perhaps	NULL
significant	NULL
is	NULL
the	NULL
observation	NULL
by	NULL
Downward	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
that	NULL
phorbol	NULL
ester	NULL
activates	NULL
predominantly	NULL
N-ras	NULL
and	NULL
Ki-ras	NULL
in	NULL
lymphocytes	NULL
.	NULL

It	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
that	NULL
PKC	NULL
activates	NULL
ras	NULL
in	NULL
a	NULL
feedback	NULL
loop	NULL
capable	NULL
of	NULL
amplifying	NULL
the	NULL
intracellular	NULL
signal	NULL
.	NULL

Both	NULL
active	NULL
ras	NULL
and	NULL
PKC	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
AP-	NULL
2697	NULL
1	NULL
(	NULL
Boyle	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Binétruy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
,	NULL
NF	NULL
«	NULL
B	NULL
(	NULL
Ghosh	NULL
and	NULL
Baltimore	NULL
,	NULL
1990	NULL
;	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
and	NULL
NF-AT	NULL
(	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
this	NULL
work	NULL
)	NULL
.	NULL

The	NULL
recent	NULL
demonstration	NULL
that	NULL
the	NULL
PKC-inducible	NULL
subunit	NULL
of	NULL
NF-AT	NULL
is	NULL
in	NULL
fact	NULL
AP-1	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
may	NULL
explain	NULL
the	NULL
ras	NULL
activation	NULL
of	NULL
NF-AT	NULL
.	NULL

These	NULL
three	NULL
transcription	NULL
factors	NULL
are	NULL
known	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
induction	NULL
of	NULL
IL-2	NULL
expression	NULL
(	NULL
reviewed	NULL
in	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
)	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
TCR	NULL
activation	NULL
of	NULL
ras	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
PKC	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
results	NULL
in	NULL
suboptimal	NULL
stimulation	NULL
of	NULL
each	NULL
of	NULL
these	NULL
factors	NULL
.	NULL

This	NULL
stimulation	NULL
is	NULL
insufficient	NULL
to	NULL
activate	NULL
IL-2	NULL
expression	NULL
fully	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
second	NULL
NF-AT	NULL
subunit	NULL
by	NULL
calcium	NULL
(	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
and	NULL
additional	NULL
activation	NULL
of	NULL
NFx	NULL
«	NULL
B	NULL
by	NULL
an	NULL
as	NULL
yet	NULL
unknown	NULL
IL-1-induced	NULL
signal	NULL
(	NULL
Espel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Baldari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
would	NULL
then	NULL
result	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
fully	NULL
competent	NULL
transcriptional	NULL
initiation	NULL
com-plexes	NULL
.	NULL

Acknowledgments	NULL
--	NULL
We	NULL
gratefully	NULL
acknowledge	NULL
G.	NULL
Crabtree	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
the	NULL
NF-AT/CAT	NULL
plasmid	NULL
.	NULL

We	NULL
thank	NULL
S.	NULL
Ricci	NULL
for	NULL
synthesis	NULL
of	NULL
oligonucleotides	NULL
,	NULL
and	NULL
G.	NULL
Corsi	NULL
for	NULL
photographic	NULL
assist-ance	NULL
.	NULL

REFERENCES	NULL
Abraham	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
Barna	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
McKean	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
2719	NULL
2728	NULL
Baldari	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
Macchia	NULL
,	NULL
G.	NULL
,	NULL
Heguy	NULL
,	NULL
A.	NULL
,	NULL
Melli	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Telford	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
19103—19108	NULL
Balggri	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
Macchia	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Telford	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
4289~	NULL
4291	NULL
Banerji	NULL
,	NULL
J.	NULL
,	NULL
Olson	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1983	NULL
)	NULL
Cell	NULL
33	NULL
,	NULL
729-740	NULL
Barbacid	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

56	NULL
,	NULL
779-827	NULL
Berry	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

189	NULL
,	NULL
205-214	NULL
Berry	NULL
,	NULL
N.	NULL
,	NULL
Ase	NULL
,	NULL
K.	NULL
,	NULL
Kishimoto	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
2294-2298	NULL
Binétruy	NULL
,	NULL
B.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
851	NULL
,	NULL
122-127	NULL
Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Smeal	NULL
T.	NULL
Deﬁze	NULL
L.	NULL
H.	NULL
K.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Woodgett	NULL
J.	NULL
R.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Hunter	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
573-584	NULL
Casagli	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Borri	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
DEtton-e	NULL
C.	NULL
,	NULL
Galeotti	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Di	NULL
Liegro	NULL
,	NULL
C.	NULL
,	NULL
Ghiara	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Antoni	NULL
,	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
Prep	NULL
.	NULL

Biochem	NULL
.	NULL

19	NULL
,	NULL
23-25	NULL
Clevers	NULL
,	NULL
H.	NULL
,	NULL
Alarcon	NULL
,	NULL
B.	NULL
,	NULL
Wileman	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Terhost	NULL
,	NULL
C.	NULL
(	NULL
1988	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
629-662	NULL
Crabtree	NULL
G.	NULL
KR	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
355-361	NULL
Dente	NULL
,	NULL
L.	NULL
,	NULL
Sollazzo	NULL
,	NULL
M.	NULL
,	NULL
Baldari	NULL
,	NULL
C	NULL
Cesareni	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Cortese	NULL
,	NULL
R.	NULL
(	NULL
1985	NULL
)	NULL
in	NULL
DNA	NULL
Clomng	NULL
A	NULL
Practical	NULL
Approach	NULL
(	NULL
Glover	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
ed	NULL
)	NULL
Vol	NULL
.	NULL

1	NULL
,	NULL
pp	NULL
.	NULL

101-107	NULL
,	NULL
IRL	NULL
Press	NULL
,	NULL
Oxford	NULL
Dinarello	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

44	NULL
,	NULL
153-205	NULL
Downward	NULL
,	NULL
J.	NULL
,	NULL
Graves	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Warne	NULL
,	NULL
P.	NULL
H	NULL
,	NULL
Rayter	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
346	NULL
,	NULL
719-723	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Belagaje	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Crabtree	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Higgins	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Crabtree	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Selence	NULL
246	NULL
,	NULL
1617	NULL
1620	NULL
Esgel9	NULL
E.	NULL
,	NULL
9Fromental	NULL
C.	NULL
,	NULL
Rexchenbach	NULL
P.	NULL
,	NULL
and	NULL
Nabholz	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
929-937	NULL
Feig	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
and	NULL
Cooper	NULL
,	NULL
G.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
3235-3248	NULL
Finkel	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Kubo	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
and	NULL
Cambier	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
12	NULL
,	NULL
79-	NULL
Flgréazgarslogst	NULL
,	NULL
Corthésy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
Fujita	NULL
,	NULL
T.	NULL
,	NULL
Shibuya	NULL
,	NULL
H.	NULL
,	NULL
Ohashi	NULL
,	NULL
T.	NULL
,	NULL
Yamanishi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
401-407	NULL
Gardner	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
15-20	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
344	NULL
,	NULL
678-682	NULL
Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Moffat	NULL
,	NULL
L.	NULL
F.	NULL
,	NULL
and	NULL
Howard	NULL
,	NULL
B.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2	NULL
,	NULL
1044-1051	NULL
Heguy	NULL
,	NULL
A.	NULL
,	NULL
Baldari	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
Bush	NULL
,	NULL
K.	NULL
,	NULL
Nagele	NULL
,	NULL
R.	NULL
,	NULL
Newton	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Robb	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Horuk	NULL
,	NULL
R	NULL
Telford	NULL
J.	NULL
L	NULL
and	NULL
Melh	NULL
,	NULL
M	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
Growth	NULL
szf	NULL
2	NULL
,	NULL
311-315	NULL
``	NULL
H15d3§6a	NULL
$	NULL
4	NULL
Inagak1	NULL
S	NULL
Kawamoto	NULL
S.	NULL
,	NULL
and	NULL
Sasaki	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
chhemtstry	NULL
23	NULL
,	NULL
1	NULL
JagglJéchaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
356	NULL
,	NULL
Korman	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Frantz	NULL
,	NULL
D.	NULL
,	NULL
Strominger	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Mulligan	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
SCL	NULL
U	NULL
.	NULL

S	NULL
A	NULL
.	NULL

84	NULL
2150-2154	NULL
Kgrzsléel3	NULL
8T	NULL
A.	NULL
,	NULL
Roberts	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Zakour	NULL
,	NULL
R	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

154	NULL
,	NULL
Lacal	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Fleming	NULL
,	NULL
T.	NULL
P.	NULL
,	NULL
Warren	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
Blumberg	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
and	NULL
Aaronson	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

7	NULL
4146-	NULL
4149	NULL
Leevers	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
Marshall	NULL
,	NULL
C	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
569-574	NULL
Lowry	NULL
,	NULL
0	NULL
.	NULL

H.	NULL
,	NULL
Rosebrough	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Farr	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
Randall	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1951	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

198	NULL
,	NULL
265-275	NULL
Macchia	NULL
,	NULL
G.	NULL
,	NULL
Baldan	NULL
C.	NULL
T.	NULL
,	NULL
Massone	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Telford	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
2731-2737	NULL
Mgﬁgr	NULL
$	NULL
a	NULL
.	NULL

H.	NULL
,	NULL
Wubbolts	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Bos	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
5963-	NULL
Muegge	NULL
,	NULL
K.	NULL
,	NULL
Williams	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Kant	NULL
,	NULL
J.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Schmidt	NULL
,	NULL
A.	NULL
,	NULL
Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
and	NULL
Durum	NULL
S.	NULL
K.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
249-251	NULL
Nishizuka	NULL
,	NULL
v.	NULL
(	NULL
1984	NULL
)	NULL
Nature	NULL
308	NULL
318-320	NULL
Price	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Morris	NULL
,	NULL
J.	NULL
D.	NULL
H.	NULL
Marshall	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Hall	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
16638—16643	NULL
2698	NULL
Santos	NULL
,	NULL
E.	NULL
,	NULL
Tronick	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Aaronson	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Pulciani	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Barbacid	NULL
,	NULL
M.	NULL
(	NULL
1982	NULL
)	NULL
ature	NULL
298	NULL
543-347	NULL
Serfling	NULL
,	NULL
E.	NULL
,	NULL
Barthelmas	NULL
R.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I	NULL
Schenk	NULL
,	NULL
B.	NULL
,	NULL
Zagxus	NULL
S.	NULL
,	NULL
Swoboda	NULL
,	NULL
R.	NULL
,	NULL
Mercuno	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
4	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B	NULL
Toole	NULL
,	NULL
J.	NULL
J.	NULL
Emmel	NULL
E	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
R	NULL
1988	NULL
)	NULL
Selence	NULL
241	NULL
,	NULL
202-	NULL
Sxebenhst	NULL
U.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Bressler	NULL
Holbrook	NULL
,	NULL
N	NULL
Norris	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Kamoun	NULL
,	NULL
N.	NULL
,	NULL
Kant	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Mol	NULL
.	NULL

Ceh	NULL
Biol	NULL
.	NULL

6	NULL
,	NULL
3042	NULL
3049	NULL
$	NULL
283	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Feig	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
and	NULL
Gibbs	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
4053-	NULL
ras	NULL
Mediates	NULL
TCR	NULL
Signal	NULL
Transduction	NULL
Thomas	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
DeMarco	NULL
,	NULL
M.	NULL
,	NULL
D'Arcangelo	NULL
,	NULL
G.	NULL
,	NULL
Halegoua	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Brugge	NULL
,	NULL
G.	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
68	NULL
,	NULL
1031-1040	NULL
Truneh	NULL
,	NULL
A.	NULL
,	NULL
Albert	NULL
,	NULL
F.	NULL
,	NULL
Golstein	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Schmitt-Verhulst	NULL
,	NULL
A.-M.	NULL
(	NULL
1985	NULL
)	NULL
Nature	NULL
313	NULL
,	NULL
318-320	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
,	NULL
Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
421-452	NULL
Wolfman	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Macara	NULL
,	NULL
I.	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
325	NULL
,	NULL
359-361	NULL
Wood	NULL
,	NULL
K.	NULL
W.	NULL
,	NULL
Sarnecki	NULL
,	NULL
C.	NULL
,	NULL
Roberts	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
Blenis	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
68	NULL
,	NULL
1041-1050	NULL

